Company: AIP
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001667011-25-000022
Chunk: 237

Company: Arteris, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part II, Item 3
Chunk 237
---
Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

69

Table of Contents

Item 5. Other Information

10b5-1 plans:

On March 5, 2025, Charles Janac, Chief Executive Officer (CEO), adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 186,757 shares of the Company’s common stock until June 30, 2026.

On March 5, 2025, Charles Janac, CEO, as the manager of Bayview Legacy, LLC, adopted a Rule 10b5-1 trading arrangement of Bayview Legacy LLC that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 840,000 shares of the Company’s common stock until June 30, 2026.

On March 6, 2025, Paul Alpern, Vice President and General Counsel, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 115,533 shares of the Company’s common stock until August 31, 2026.

On March 7, 2025, Raman Chitkara, Director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 15,000 shares of the Company’s common stock until June 30, 2026.

On March 12, 2025, Laurent Moll, Chief Operating Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 204,974 shares of the Company’s common stock until June 30, 2026.

70

Table of Contents

Item 6. Exhibits

Exhibit No.Description of ExhibitFormExhibitFiling DateFiled Herewith3.1Amended and Restated Certificate of Incorporation of Arteris, Inc.8-K3.110-29-20213.2Amended and Restated Bylaws of Arteris, Inc.8-K3.210-29-20214.1Specimen Stock Certificate evid